Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ENZALUTAMIDE Cause Cerebrovascular accident? 595 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 595 reports of Cerebrovascular accident have been filed in association with ENZALUTAMIDE (Xtandi). This represents 1.2% of all adverse event reports for ENZALUTAMIDE.

595
Reports of Cerebrovascular accident with ENZALUTAMIDE
1.2%
of all ENZALUTAMIDE reports
121
Deaths
284
Hospitalizations

How Dangerous Is Cerebrovascular accident From ENZALUTAMIDE?

Of the 595 reports, 121 (20.3%) resulted in death, 284 (47.7%) required hospitalization, and 19 (3.2%) were considered life-threatening.

Is Cerebrovascular accident Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ENZALUTAMIDE. However, 595 reports have been filed with the FAERS database.

What Other Side Effects Does ENZALUTAMIDE Cause?

Fatigue (8,891) Death (6,680) Malignant neoplasm progression (4,696) Prostatic specific antigen increased (3,731) Asthenia (3,589) Drug ineffective (3,468) Hot flush (3,144) Decreased appetite (3,069) Nausea (2,898) Dizziness (2,776)

What Other Drugs Cause Cerebrovascular accident?

ROSIGLITAZONE (7,899) APIXABAN (7,237) RIVAROXABAN (4,111) ADALIMUMAB (2,756) LENALIDOMIDE (2,330) DABIGATRAN ETEXILATE (2,175) TESTOSTERONE (2,172) ASPIRIN (1,904) SACUBITRIL\VALSARTAN (1,864) INSULIN GLARGINE (1,805)

Which ENZALUTAMIDE Alternatives Have Lower Cerebrovascular accident Risk?

ENZALUTAMIDE vs EPCORITAMAB ENZALUTAMIDE vs EPCORITAMAB-BYSP ENZALUTAMIDE vs EPERISONE ENZALUTAMIDE vs EPHEDRINE ENZALUTAMIDE vs EPINASTINE

Related Pages

ENZALUTAMIDE Full Profile All Cerebrovascular accident Reports All Drugs Causing Cerebrovascular accident ENZALUTAMIDE Demographics